TY - JOUR T1 - Biomarker Analyses in Patients With Advanced Solid Tumors Treated With the LAT1 Inhibitor JPH203 JF - In Vivo JO - In Vivo SP - 2595 LP - 2606 DO - 10.21873/invivo.12077 VL - 34 IS - 5 AU - NAOHIRO OKANO AU - KIYOMI HANA AU - DAISUKE NARUGE AU - KIRIO KAWAI AU - TAKAAKI KOBAYASHI AU - FUMIO NAGASHIMA AU - HITOSHI ENDOU AU - JUNJI FURUSE Y1 - 2020/09/01 UR - http://iv.iiarjournals.org/content/34/5/2595.abstract N2 - Background/Aim: Amino acids are among the most important nutrients for supplying energy and building protein blocks in cancers. L-type amino acid transporter (LAT) 1 is known to play a critical role in cancer growth. We have completed the first-in-human phase I study using the LAT1-specific inhibitor JPH203. Patients and Methods: We evaluated plasma free amino acids (PFAAs), body mass index (BMI), and efficacy of JPH203 in patients enrolled in the phase I study. Results: LAT1-substrate PFAAs and branched chain amino acids (BCAAs) were higher in patients with biliary tract cancer (BTC) than in those with other cancers. High inhibition of uptake of LAT1-substrate PFAAs was associated with survival. BMI of more than the median was associated with disease control and survival. BCAAs tended to be associated with BMI. Conclusion: BCAAs and BMI are useful predictors of the efficacy of JPH203, which shows promising activity against BTC. ER -